Clinical Trials
26 trialsBuMelMCRN001
University Health Network, Toronto
CARTITUDE-2
Janssen Research & Development, LLC
MajesTEC-2
Janssen Research & Development, LLC
CARTITUDE-5
Janssen Research & Development, LLC
MonumenTAL-2
Janssen Research & Development, LLC
A Study of Daratumumab
Janssen Research & Development, LLC
MajesTEC-7
Janssen Research & Development, LLC
aMMbition
Janssen Research & Development, LLC
MajesTEC-4
European Myeloma Network B.V.
FASTER
SCRI Development Innovations, LLC
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
PLYCOM
Hoffmann-La Roche
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
MASTER-2
University of Alabama at Birmingham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
ElLen
Intergroupe Francophone du Myelome
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
Celgene
REVALLO
University Hospital, Bordeaux
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
M.D. Anderson Cancer Center
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
PrE1005
PrECOG, LLC.